Practical Dermatology

01/01/2026

🎇🎇 Happy New Year from the entire team at Practical Dermatology! We looks forward to bringing our audience the most informative coverage of the people, stories, breakthroughs, and conferences driving dermatology in 2026! 🎆🎆

12/31/2025

✅ 📋ICYMI: Be sure not to miss Practical Dermatology Chief Medical Editor Neal Bhatia, MD, as he and Dr. Jules Lipoff, Adjunct Clinical Associate Professor in the Lewis Katz School of Medicine at Temple University, provide tips and insights into working ethically with industry partners.👩‍⚕️✨

🎧Listen here ➡️ https://ow.ly/ALLI50XNSmf

Former Chair of the Board of Directors for the National Psoriasis Foundation Colby Evans, MD, provides an update on the SAFE Step Act, and...

12/30/2025

🔎📊NEW: A recent study from China indicates a link between gut barrier dysfunction and atopic dermatitis symptoms, with early evidence suggesting serum D-lactate could help predict which patients will respond best to microbiota-based therapies like WMT. 🩺

Read more ➡️ https://ow.ly/s5hx50XQaHY

12/29/2025

🎙️👩‍⚕️NEW PRACTICAL DERMATOLOGY PODCAST: In this episode, Mona Shahriari, MD, FAAD, talks about the challenges psoriasis poses in certain parts of the body such as the scalp and nails, plus Brittany Craiglow, MD, FAAD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss the latest advances in alopecia areata.

🎧Listen here ➡️ https://ow.ly/lS2A50XNSgG

Mona Shahriari, MD, FAAD, talks about the challenges psoriasis poses in certain parts of the body such as the scalp and nails, plus Brittany...

12/26/2025

📊 CONTRACEPTION AND ACNE: Acne incidence in LNG-IUS users is dose- and age-dependent, according to results from a new analysis. Among over 6,000 users, those using the 52 mg device had higher acne rates, especially younger women.

Read more ➡️ https://ow.ly/VJqx50XNS4M

12/25/2025

🎄🎄 Merry Christmas and Happy Holidays from the whole team at Practical Dermatology!🎄🎄

12/24/2025

☀️ 🔎 NEW: A recent analysis of Amazon’s top-selling sunless tanners finds that while DHA is a consistent active ingredient, only 3% of products offer built-in SPF. Adverse skin reactions, including contact dermatitis and pigmentary changes, were noted in almost 2% of user reviews. 🩺

Read more ➡️ https://ow.ly/9AJV50XNRrf

12/23/2025

📊🧴ROFLUMILAST EFFECTIVE IN HS: A small prospective case series found patients treated with once-daily topical roflumilast 0.3% cream saw improved lesions and symptoms in mild hidradenitis suppurativa (HS), and with no adverse events reported.✨

Read more ➡️ https://ow.ly/f9mC50XNnSO

12/22/2025

🎙️👩‍⚕️NEW PRACTICAL DERM PODCAST: Jennifer Cather, MD, and Melodie Young ASN, RN, discuss recent consensus statements from the Ge***al Psoriasis Wellness Consortium, and J. Scott Boswell, MD, joins Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, to discuss his boot camp for nurse practitioners and physician associates in dermatology.🩺 🔊

🎧Listen here ➡️ https://ow.ly/OQqw50XNgRU

***alPsoriasis

Jennifer Cather, MD, and Melodie Young ASN, RN, discuss recent consensus statements from the Ge***al Psoriasis Wellness Consortium, and Scott...

12/20/2025

🧪🩺 NEW: , a monoclonal antibody targeting OSMRβ, was linked with dose-dependent improvements in itch and lesion clearance in patients with moderate to severe prurigo nodularis (PN) over a period of 16 weeks (with a favorable safety profile). High-dose vixarelimab achieved > 50% reduction in WI-NRS and IGA 0/1 scores in over a third of patients.

Read more ➡️ https://ow.ly/txsw50XMNyx

12/19/2025

💊🔎📊 ZASOCITINIB SHOWS POTENTIAL IN PHASE 3 STUDY: Novel oral TYK2 inhibitor zasocitinib (TAK-279) met all primary and 44 ranked secondary endpoints in two pivotal phase 3 trials for moderate-to-severe plaque psoriasis, according to a December 18 press release from Takeda. The company plans to file a New Drug Application with the FDA in 2026.

Read more ➡️ https://ow.ly/MJil50XMy2q

12/18/2025

💉 💰 IS BTX FOR HYPERHIDROSIS COVERED? A new study suggests most major U.S. insurers now cover botulinum toxin (BTX) for primary axillary hyperhidrosis, but patients still face financial hurdles. Study authors urged better education around insurance policies and support programs to reduce cost barriers.

Read more ➡️ https://ow.ly/tL6y50XKpB4